Apolymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera

Blood

Volumn 119, Issue 22, 2012, Pages 5221-5228

  Hernández Boluda, Juan Carlos ^a   Pereira, Arturo ^b   Cervantes, Francisco ^c   Alvarez Larrán, Alberto ^d   Collado, María ^a   Such, Esperanza ^e   Jesus Arilla M ^f   Boqué, Concepción ^g   Xicoy, Blanca ^h   Maffioli, Margherita ^c   Bellosillo, Beatriz ^d   Marugán, Isabel ^a   Amat, Paula ^a   Besses, Carles ^d   Guillem, Vicent ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL DE SAGUNTO   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PHOSPHORUS 32; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ERCC2 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CODON; DIGESTIVE SYSTEM CANCER; DNA POLYMORPHISM; DNA REPAIR; DRUG EXPOSURE; EXON; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; ONCOGENESIS AND MALIGNANT TRANSFORMATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CANCER; THROMBOCYTHEMIA; URINARY TRACT CANCER; CHILD; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS; INFANT; LEUKEMIA; META ANALYSIS; METABOLISM; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA; MALE; POLYCYTHEMIA VERA; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; THROMBOCYTHEMIA, ESSENTIAL; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84861862406     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-411215     Document Type: Article

References (43)

1. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905-914.
2. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21(2):270-276.
3. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664-2670.
4. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645-1651.
5. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23(2):132-143.
6. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29(29):3907-3913.
7. Björkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29(17):2410-2415.
8. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998;91(2):616-622.
9. Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sorensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011;118(25):6515-6520.
10. Fallah M, Kharazmi E, Sundquist J, Hemminki K. Higher risk of primary cancers after polycythaemia vera and vice versa. Br J Haematol. 2011;153(2):283-285.
11. Vannucchi AM, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2068-2073.
12. Navarro CL, Cau P, Levy N. Molecular bases of progeroid syndromes. Hum Mol Genet. 2006;15 Spec No 2:R151-161.
13. David SS, O'Shea VL, Kundu S. Base-excision repair of oxidative DNA damage. Nature. 2007;447(7147):941-950.
14. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1(1):22-33.
15. Matullo G, Dunning AM, Guarrera S, et al. DNA repair polymorphisms and cancer risk in nonsmokers in a cohort study. Carcinogenesis. 2006;27(5):997-1007.
16. Allan JM, Smith AG, Wheatley K, et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood. 2004;104(13):3872-3877.
17. Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood. 2002;100(10):3761-3766.
18. Wang F, Chang D, Hu FL, et al. DNA repair gene XPD polymorphisms and cancer risk: a metaanalysis based on 56 case-control studies. Cancer Epidemiol Biomarkers Prev. 2008;17(3):507-517.
19. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1513-1530.
20. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008; 22(1):14-22.
21. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446-449.
22. Solé X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22(15):1928-1929.
23. Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007;138(3):354-358.
24. Burgstaller S, Kreil S, Waghorn K, et al. The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. Leukemia. 2007;21(12):2428-2432.
25. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood. 2008;111(5):2785-2789.
26. Pardanani A, Lasho TL, Finke CM, et al. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia. 2010;24(1):110-114.
27. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112(6):2199-2204.
28. Bhatia S. Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2048-2067.
29. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32(4 Pt 2):417-421.
30. Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363-1369.
31. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000;110(3):577-583.
32. Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood. 1997;89(7):2319-2327.
33. Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood. 2000;95(11):3589-3593.
34. Burkitt MJ, Raafat A. Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders. Blood. 2006;107(6):2219-2222.
35. Sanchez-Palacios C, Guitart J. Hydroxyurea-associated squamous dysplasia. J Am Acad Dermatol. 2004;51(2):293-300.
36. Francis AA, Blevins RD, Carrier WL, Smith DP, Regan JD. Inhibition of DNA repair in ultraviolet-irradiated human cells by hydroxyurea. Biochim Biophys Acta. 1979;563(2):385-392.
37. Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE. The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica. 2011;96(3):450-453.
38. Lehmann AR. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev. 2001;15(1):15-23.
39. Fuss JO, Tainer JA. XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase. DNA Repair (Amst). 2011;10(7):697-713.
40. Coin F, Marinoni JC, Rodolfo C, Fribourg S, Pedrini AM, Egly JM. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat Genet. 1998;20(2):184-188.
41. Holstege FC, van der Vliet PC, Timmers HT. Opening of an RNA polymerase II promoter occurs in two distinct steps and requires the basal transcription factors IIE and IIH. EMBO J. 1996;15(7):1666-1677.
42. Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis. 2002;17(6):463-469.
43. Smith AG, Worrillow LJ, Allan JM. A common genetic variant in XPD associates with risk of 5q-and 7q-deleted acute myeloid leukemia. Blood. 2007;109(3):1233-1236.